SLC5A1 and prostate carcinoma: A previous study showed that inhibition of sodium/glucose cotransporter 1 (SGLT1) sensitized prostate cancer cells to EGFR inhibitors (gefitinib and erlotinib) (Wright et al., 2011), although the precise mechanisms have not been elucidated.